CD274 and non-small cell lung carcinoma: <h4>Background</h4>Pembrolizumab monotherapy is the standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) with programmed cell death ligand-1 (PD-L1) expression ≥ 50%.